ArticleJournal of neurology2025
Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Long-Term Prospective Evaluation of the Predictive Value of Molecular Markers in Serum and Cerebrospinal Fluid in Patients in the Early Stage of Multiple Sclerosis.International journal of molecular sciences · 2026Article
- Assessing Peripheral Blood Biomarkers and Predictive Patterns in Multiple Sclerosis Using Cytokines and Immune Gene Expression Profiles in Ocrelizumab-Treated Patients: Tracking Tumor Necrosis Factor.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatform therapies, such as dimethylfumarate, teriflunomide, and interferons beta, are insufficient to control relapsing-remitting multiple sclerosis in many patients. Having biomarkers available to stratify patients as good or poor responders before starting treatment would represent a considerable advance.
methodsWe tested serum and cerebrospinal fluid (CSF) levels of chitinase 3-like 1 (c and s-CHI3L1), soluble trigger receptor expressed on myeloid cells (sTREM2) and neuronal pentraxin 2 (NPTX2), and CSF levels of neurofilament light chains and of interleukin-6 (c-IL6) collected before treatment start in 70 patients in Eastern France. We explored associations with the status responder or non-responder after 12 months of efficient treatment. Non-responders were defined as patients with sign of activity, or confirmed increase of disability, or treatment cessation due to « inefficacy» according to the treating physician.
results39 patients were non-responders (55.7%). c-CHI3L1 taken as a binary variable (under or above 164.6 ng/mL) and c-IL6 either as a binary variable (detectable or not) were associated with being non-responders. The positive predictive value of being non-responder in case of c-CHI3L1 higher than 164.6 ng/mL was 0.63 (95 confidence interval 95CI 0.43-0.82). No responder patients had detectable c-IL6, 12 non-responders (46.2%) had detectable c-IL6. Having high values of c-CHI3L1 and/or detectable c-IL6 was associated with an 8.33 higher risk of being non-responder after 1 year of effective platform treatment (95CI 1.44-33.33; p = 0.001).
conclusionsCHI3L1 and IL6 in CSF could predict the first-year response to platform therapies.
Indexed as
Identifiers
40855223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.